Journals / art / 2019 / Cilt: 34 - Sayı: 1

Changes in Serum Levels of Type-III Interferons in Ankylosing Spondylitis Treated With Tumor Necrosis Factor-Alpha Inhibitors

Journal
art
Pages
9–17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These findings indicate that type-III IFNs may be involved in the pathogenesis of AS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to determine the changes in serum levels of type-III interferons (type-III IFNs) in ankylosing spondylitis (AS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) and analyze the correlations between serum type-III IFN levels and disease activity.
📊
Key Findings & Data:Patients and methods: The study included 57 AS patients (51 males, 6 females; mean age 29.7±7.0 years; range, 18 to 50 years), who had been diagnosed with AS and had active disease before the start of the study (median disease duration: four years, range 1.3 to 8.0 years).
💡
Conclusion & Impact:Conclusion: These findings indicate that type-III IFNs may be involved in the pathogenesis of AS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aims to determine the changes in serum levels of type-III interferons (type-III IFNs) in ankylosing spondylitis (AS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) and analyze the correlations between serum type-III IFN levels and disease activity. Patients and methods: The study included 57 AS patients (51 males, 6 females; mean age 29.7±7.0 years; range, 18 to 50 years), who had been diagnosed with AS and had active disease before the start of the study (median disease duration: four years, range 1.3 to 8.0 years). Control group included 50 healthy, age- and sex-matched individuals (45 males, 5 females; mean age 25.5±6.7 years; range, 18 to 55 years). The enzyme-linked immunosorbent assay was used to assess the serum interleukin (IL)-29, IL-28A, and IL-28B levels of AS patients at baseline and first, third, sixth months after treatment with TNFi. Clinical and laboratory features of the disease were also evaluated for AS patients at baseline and first, third, sixth months after treatment. Results: Serum IL-28A levels were significantly higher in AS patients (354.8±164.0 pg/mL) than in controls (257.2±99.6, p=0.003) at baseline. Serum IL-28B levels were significantly lower in AS patients (median, 491.4 pg/mL, range 296.6 to 944.6 pg/mL) than in controls (1121.1±409.3 pg/mL, p=0.000) at baseline. Serum IL-29 levels at third month after treatment (median 430.9, range 277.4 to 1023.9 pg/mL) were significantly increased compared with baseline (median 399.1, range 261.2 to 826.7 pg/mL), p=0.002) and controls (335.2±100.5 pg/mL, p=0.041). There was no association between serum type-III IFN levels and disease activity indexes at baseline. Serum levels of IL-28A were negatively correlated with erythrocyte sedimentation rate levels at first and sixth months after treatment (r=-0.266, p=0.046; r=-0.286, p=0.034, respectively). Serum levels of IL-28A were negatively correlated with Bath Ankylosing Spondylitis Disease Activity Index at third month after treatment (r=-0.269, p=0.043). Serum levels of IL-29 were negatively correlated with Bath Ankylosing Spondylitis Disease Activity Index at third month after treatment (r=-0.299, p=0.024). There was a significant increasing trend for serum IL-28B after TNFi treatment in AS patients, opposite to the decreasing trend for disease activity. Conclusion: These findings indicate that type-III IFNs may be involved in the pathogenesis of AS. Thus, type-III IFNs may provide new targets for the treatment of AS.

🔖

Cite This Article

JIAO1, D., CHANG, Q., Lİ, P. (2019). Changes in Serum Levels of Type-III Interferons in Ankylosing Spondylitis Treated With Tumor Necrosis Factor-Alpha Inhibitors. art, Cilt: 34 - Sayı: 1, 9–17. https://ajindex.com/articles/149683

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90
  2. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158
  3. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164-71
  4. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8
  5. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie 2007;89:729-34
  6. Dickensheets H, Sheikh F, Park O, Gao B, Donnelly RP. Interferon-lambda (IFN-l) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes. J Leukoc Biol 2013;93:377-85
  7. Wu Q, Yang Q, Sun H, Li M, Zhang Y, La Cava A. Serum IFN-l1 is abnormally elevated in rheumatoid arthritis patients. Autoimmunity 2013;46:40-3
  8. Amezcua-Guerra LM, Ferrusquía-Toriz D, Castillo- Martínez D, Márquez-Velasco R, Chávez-Rueda AK, Bojalil R. Limited effectiveness for the therapeutic blockade of interferon a in systemic lupus erythematosus: a possible role for type III interferons. Rheumatology (Oxford) 2015;54:203-5
  9. Dantas AT, Gonçalves SM, Pereira MC, de Almeida AR, Marques CD, Rego MJ, et al. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). Autoimmunity 2015;48:429-33
  10. Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, et al. IFN-l resolves inflammation via suppression of neutrophil infiltration and IL-1b production. J Exp Med 2015;212:845-53
  11. Qiu C, Li Y, Zhou M, Liu J, Li M, Wu Y, et al. Hydrodynamic delivery of IL-28B (IFN-l3) gene ameliorates lung inflammation induced by cigarette smoke exposure in mice. Biochem Biophys Res Commun 2014;447:513-9
  12. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 2007;8:13-20
  13. Mennechet FJ, Uzé G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006;107:4417-23. 14. van der Linden S, Valkenburg HA, Cats A. E